Correction: Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

Walker JW, Lebbé C, Grignani G, *et al.* Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. *J Immunother Cancer* 2020;8:e000313. doi: 10.1136/jitc-2019-000313.

Since the online publication of this article, the authors have noticed errors in Table 1 and 2. In Table 1, the header 'Approved immunocompromised patients (n=33)' should read 'Approved immunocompromised patients (n=37)' as the total number of patients is 37. Additionally in Table 2 row 'CR', column '1L (n=15)', the data value is incorrectly stated as '5 (33.3)2 (13.3)'. The correct data value is '2 (13.3)'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000313corr1. doi:10.1136/jitc-2019-000313corr1